MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease

This study is ongoing, but not recruiting participants.

First Received: March 9, 2006 Last Updated: August 17, 2007 History of Changes

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00302471

Purpose

This study will evaluate the safety and effectiveness of an experimental medicine (MK0429) in men with metastatic prostate cancer that no longer respond to hormone therapy.

Condition	Intervention	Phase
Prostatic Neoplasms	Drug: MK0429	Phase I

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date:

March 2006

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Eligible patients must have: 1) prostate cancer, 2) bone metastases without symptoms, 3) lack of response to hormone therapy as evidenced by a rising PSA or clinical progression

Exclusion Criteria:

Prostate cancer-related bone pain
Previously received bisphosphonate therapy (e.g. zoledronate)
Received any investigational treatment within the last 30 days

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00302471

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Study ID Numbers:	2006_013
Study First Received:	March 9, 2006
Last Updated:	August 17, 2007
ClinicalTrials.gov Identifier:	NCT00302471 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms

Genital Diseases, Male
Bone Diseases
Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on September 02, 2009